Journal
PATHOLOGY RESEARCH AND PRACTICE
Volume 218, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.prp.2020.153322
Keywords
Gastric cancer; Immunosurveillance; Immunoescape; Immunotherapy; Adoptive cell therapy; Cancer vaccine; Immune checkpoint
Categories
Funding
- Zhejiang Medical Technology Plan Project [2017KY007]
Ask authors/readers for more resources
Gastric cancer is the third leading cause of deaths and the fifth most common cancers worldwide. Traditional treatment approaches include chemotherapy, radiation, surgery, and targeted therapy. Immunotherapy has shown promising results, but the prognosis remains poor.
Gastric cancer is considered as the third leading cause of deaths and the fifth most common cancers worldwide. Common treatment approaches include chemotherapy, radiation, gastric resection and targeted therapies. The emergence of gastric cancer immunotherapy has already shown some promising results and have altered the therapeutic procedures. Now, different combination therapies as well as novel immunotherapies targeting new molecules have been proposed. Despite ongoing investigations on the therapeutic options and significant advancements in this regard, the disease is poorly prognosed. In fact, limited therapeutic options and delayed diagnosis lead to the progression, dissemination and metastasis of the disease. Current immunotherapies are mostly based on cytotoxic immunocytes, monoclonal antibodies and gene transferred vaccines. The use of Immune checkpoint inhibitors (ICIs) have grown rapidly. In this review, we aimed to explore perspective and progression of different approaches of immunotherapy in the treatment of GC and the clinical outcomes reported so far. We also summarized the tumor immunosurveillance and tumor immunoescape.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available